Sara Garcia-Rates | Neuroscience | Research Excellence Award

Published on by Awards and Recognitions

Research Excellence Award

Sara Garcia-Rates
Neuro Bio Ltd, United Kingdom
Sara Garcia-Rates
Affiliation Neuro Bio Ltd
Country United Kingdom
Scopus ID 23388862700
Documents 26
Citations 336
h-index 11
Subject Area Neuroscience
Event Research Awards and Recognitions
ORCID 0000-0002-1848-4811

Sara Garcia-Rates is a neuroscience researcher and biotechnology executive associated with Neuro Bio Ltd. With more than two decades of experience, her work focuses on neuroscience, neurodegenerative diseases, translational medicine, and biotechnology innovation. She has contributed to Alzheimer’s disease research through leadership in preclinical drug development, assay validation, intellectual property strategy, and scientific collaboration. Her academic background in pharmacology and biomedicine supports her role in advancing therapeutic development and translational research. Garcia-Rates combines scientific leadership with commercialization strategy, contributing to biomedical innovation and the development of novel approaches for neurodegenerative disease treatment.[1]

Abstract

Sara Garcia-Rates is a multidisciplinary neuroscience researcher specializing in neurodegenerative disease therapeutics, Alzheimer’s disease drug discovery, and translational biotechnology. Her work includes developing preclinical research strategies, expanding biotechnology patent portfolios, and advancing therapeutic candidates through international scientific collaborations. She has also contributed to neuropharmacology research focused on nicotinic receptor biology, neurotoxicity mechanisms, and receptor-mediated signaling pathways, establishing a strong profile in neuroscience innovation and therapeutic development.[2]

Keywords

Neuroscience, Alzheimer’s disease, neuropharmacology, biotechnology, translational medicine, preclinical development, nicotinic receptors, neurodegeneration, therapeutics, pharmacology, biotechnology leadership, drug discovery, intellectual property, neuroscience innovation.

Introduction

Sara Garcia-Rates has built an interdisciplinary research profile combining neuroscience, biotechnology, and translational medicine. Her work focuses on neurodegenerative diseases, neuronal signaling, receptor modulation, and therapeutic development, alongside contributions to biotechnology management, patent development, research funding, and scientific collaborations.[3]

Sara Garcia-Rates received advanced training in biology, pharmacology, and biomedicine at the University of Barcelona and completed postdoctoral research at the University of Oxford Department of Pharmacology. Her career combines academic neuroscience research with biotechnology leadership, focusing on translational biomedical science and therapeutic innovation.[2]

Research Profile

Sara Garcia-Rates serves as Chief Scientific Officer at Neuro Bio Ltd, where she has contributed since 2013. Her work includes leading preclinical neuroscience research, therapeutic development, experimental assay design, and intellectual property strategy. [1]

Her leadership includes overseeing scientific projects, managing multidisciplinary teams, and coordinating collaborative partnerships. Under her direction, the organization expanded its patent portfolio from two patents to twenty-two patent families related to neurodegeneration, oncology, anti-aging research, and therapeutic technologies.[4]

Sara Garcia-Rates has also contributed to funding acquisition strategies, scientific advisory board activities, and partnerships with universities, contract research organizations, and industrial collaborators. These activities illustrate the integration of scientific research with translational commercialization and innovation management within the biotechnology sector.[5]

Research Contributions

Garcia-Rates has contributed to neuroscience research on nicotinic receptors, neurotoxicity, intracellular signaling, and the effects of methamphetamine and MDMA exposure. Her studies focus on receptor-mediated pathways, oxidative stress, and neurochemical regulation in experimental systems.[2]

Her translational research includes developing therapeutic candidates for Alzheimer’s disease at Neuro Bio Ltd. She contributed to the evaluation and optimization of nearly two hundred compounds, supporting the development of preclinical therapies and patent-protected technologies for neurodegenerative disorders.[4]

Additional contributions include establishment of research partnerships across the United Kingdom and international biotechnology networks. Her work in collaborative development has supported external scientific collaborations, intellectual property growth, and strategic development of biotechnology assets involving therapeutic and diagnostic innovation.[5]

  • Leadership of Alzheimer’s disease therapeutic development programs.
  • Expansion of biotechnology patent portfolios and translational research assets.
  • Research on nicotinic receptor pharmacology and neurotoxicity.
  • Coordination of interdisciplinary scientific collaborations and advisory activities.
  • Management of preclinical neuroscience development programs.

Publications

Sara Garcia-Rates has published research in neuropharmacology, receptor biology, and neuroscience, focusing on neurotoxicity, nicotinic receptor regulation, intracellular signaling, and neurochemical mechanisms. Her work contributes to the understanding of receptor-mediated neurological disorders and includes both scientific journal articles and book chapters on methamphetamine- and MDMA-related neurotoxicity.[2]

  1. Garcia-Ratés S, Camarasa J, Escubedo E, Pubill D. Methamphetamine and 3,4-methylenedioxymethamphetamine interact with central nicotinic receptors and induce their upregulation. Toxicology and Applied Pharmacology, 2007.
  2. Chipana C, García-Ratés S, Camarasa J, Pubill D, Escubedo E. Different oxidative profile and nicotinic receptor interaction of amphetamine and MDMA. Neurochemistry International, 2008.
  3. Garcia-Ratés S, Camarasa J, Sánchez-García AI, Gandía L, Escubedo E, Pubill D. Effects of MDMA on nicotinic receptors and intracellular calcium increase. Toxicology and Applied Pharmacology, 2010.
  4. Pubill D, Garcia-Ratés S, Camarasa J, Escubedo E. Neuronal nicotinic receptors as new targets for amphetamine derivatives. Pharmaceuticals, 2011.

Research Impact

The research activities of Sara Garcia-Rates demonstrate impact across both academic neuroscience and biotechnology innovation. Her publication metrics include twenty-six indexed documents, more than three hundred citations, and an h-index of eleven, reflecting measurable scholarly engagement within the neuroscience research community.[1]

Garcia-Rates has contributed to biotechnology development through preclinical therapeutic research, patent expansion, and translational neuroscience projects focused on neurodegenerative diseases. She has also supported commercialization efforts, investment acquisition, and research funding to advance biotechnology innovation and organizational growth.[4]

Her scientific leadership has also included mentoring activities, partnership development with academic institutions, and participation in scientific advisory initiatives. These contributions indicate broader influence beyond publication metrics alone, extending into organizational development and interdisciplinary scientific collaboration.[5]

Award Suitability

Sara Garcia-Rates combines expertise in neuroscience research, translational biomedical science, and biotechnology leadership. Her work in therapeutic development, scientific publications, intellectual property expansion, and collaborative research reflects sustained contributions to neuroscience and biotechnology innovation.[3]

Her ability to lead multidisciplinary scientific projects and contribute to translational therapeutic development highlights her role in modern biomedical research. Her work in therapeutic innovation, patent expansion, and scientific collaboration demonstrates continued engagement in neuroscience research and biotechnology advancement.[4]

Conclusion

Sara Garcia-Rates has built a multidisciplinary career in neuroscience research, biotechnology leadership, and therapeutic development. Through her work at Neuro Bio Ltd and her scientific publications, she has contributed to neuropharmacology research, Alzheimer’s disease therapeutics, and biotechnology innovation.[5]

References

  1. Elsevier. (n.d.). Scopus author details: Sara Garcia-Rates, Author ID 23388862700. Scopus. https://www.scopus.com/authid/detail.uri?authorId=23388862700
  2. Garcia-Ratés S, Camarasa J, Escubedo E, Pubill D. (2007). Methamphetamine and 3,4-methylenedioxymethamphetamine interact with central nicotinic receptors and induce their upregulation. Toxicology and Applied Pharmacology. https://doi.org/10.1016/j.taap.2007.05.019
  3. Pubill D, Garcia-Ratés S, Camarasa J, Escubedo E. (2011). Neuronal nicotinic receptors as new targets for amphetamine derivatives. Pharmaceuticals. https://doi.org/10.3390/ph4060822
  4. Neuro Bio Ltd. (2025). Research development activities, patent portfolio expansion, and preclinical neuroscience initiatives. 
  5. Awards and Recognitions. (n.d.). Research Awards and Recognitions official website. https://awardsandrecognitions.com/

Hongxiao Lv | Neuroscience | Best Researcher Award

Published on by Awards and Recognitions

Dr. Hongxiao Lv | Neuroscience | Best Researcher Award

Dr. Hongxiao Lv | Neuroscience | Hebei University of Chinese Medicine | China

Dr. Hongxiao Lv is a dedicated and emerging researcher in the field of Traditional Chinese Medicine (TCM), particularly specializing in TCM syndrome differentiation and the treatment strategies for ischemic cerebrovascular diseases. Dr. Hongxiao Lv holds a comprehensive academic background, having completed a Bachelor’s degree in Chinese Materia Medica, followed by a Master’s degree in Acupuncture and Tuina, and currently pursuing doctoral research in TCM Diagnostics at Hebei University of Chinese Medicine, enabling her to integrate theoretical, clinical, and practical dimensions of TCM into her research endeavors. Her professional experience includes participating in academic research projects focused on the clinical mechanisms and therapeutic pathways of cerebrovascular disorders, contributing both analytical insights and evidence-based clinical viewpoints. She has authored and contributed to academic literature, including four research publications indexed in reputable scientific platforms and the book Practical Technologies of Traditional Chinese Medicine, which reflects her commitment to advancing clinical knowledge dissemination. Her research interests emphasize understanding pathogenesis patterns in ischemic cerebrovascular diseases, exploring diagnostic precision through syndrome differentiation, and developing treatment frameworks based on classical TCM theory combined with contemporary evidence-informed medical practice. Her research skills include TCM clinical syndrome analysis, integrative diagnostic interpretation, literature synthesis, experimental data review, research reporting, and collaboration in interdisciplinary research groups. She is a member of the Professional Committee on Integration of Traditional Chinese Medicine and Western Medicine, demonstrating her involvement in promoting the convergence of traditional therapeutic wisdom with modern biomedical practices. Awards and honors associated with her academic journey include recognition for scholarly merit, research performance, and program-based distinctions. In conclusion, Dr. Hongxiao Lv represents a committed young scholar with the ability to bridge traditional diagnostic systems with modern clinical challenges, contributing to the development of integrative treatment approaches in cerebrovascular disease management, and she continues to show promising potential for further academic growth, broader research collaboration, and international impact in the evolving field of Traditional Chinese Medicine research.

Academic Profile: ORCID

Featured Publication:

Lv, H. (n.d.). Research progress on the role of oxidative stress in the pathogenesis of vascular dementia and its treatment.